Cancer Therapy

Company reaches full enrollment in phase II non-small cell lung cancer trial

Published in Vaccine Weekly, June 16th, 2004

NovaRx Corp. has successfully achieved full enrollment more than a year ahead of schedule in its multicenter phase II clinical trial treating individuals with advanced stages of lung cancer.

The phase II study is designed to determine the safety and efficacy of a novel therapeutic concept under development by NovaRx. In contrast to conventional cancer therapies, where chemotherapeutic drugs destroy the tumor, the therapeutic vaccine developed by NovaRx enhances the patient's own immune system in order to fight the cancer. In clinical studies to date, the side effects of this treatment have been shown to be far less than those associated with traditional...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-06-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry